Cargando…
Agomelatine: A Potential Multitarget Compound for Neurodevelopmental Disorders
Agomelatine (AGM) is one of the latest atypical antidepressants, prescribed exclusively for the treatment of depression in adults. AGM belongs to the pharmaceutical class of melatonin agonist and selective serotonin antagonist (“MASS”), as it acts both as a selective agonist of melatonin receptors M...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216109/ https://www.ncbi.nlm.nih.gov/pubmed/37239206 http://dx.doi.org/10.3390/brainsci13050734 |
_version_ | 1785048219869249536 |
---|---|
author | Savino, Rosa Polito, Anna Nunzia Marsala, Gabriella Ventriglio, Antonio Di Salvatore, Melanie De Stefano, Maria Ida Valenzano, Anna Marinaccio, Luigi Bellomo, Antonello Cibelli, Giuseppe Monda, Marcellino Monda, Vincenzo Messina, Antonietta Polito, Rita Carotenuto, Marco Messina, Giovanni |
author_facet | Savino, Rosa Polito, Anna Nunzia Marsala, Gabriella Ventriglio, Antonio Di Salvatore, Melanie De Stefano, Maria Ida Valenzano, Anna Marinaccio, Luigi Bellomo, Antonello Cibelli, Giuseppe Monda, Marcellino Monda, Vincenzo Messina, Antonietta Polito, Rita Carotenuto, Marco Messina, Giovanni |
author_sort | Savino, Rosa |
collection | PubMed |
description | Agomelatine (AGM) is one of the latest atypical antidepressants, prescribed exclusively for the treatment of depression in adults. AGM belongs to the pharmaceutical class of melatonin agonist and selective serotonin antagonist (“MASS”), as it acts both as a selective agonist of melatonin receptors MT1 and MT2, and as a selective antagonist of 5-HT2C/5-HT2B receptors. AGM is involved in the resynchronization of interrupted circadian rhythms, with beneficial effects on sleep patterns, while antagonism on serotonin receptors increases the availability of norepinephrine and dopamine in the prefrontal cortex, with an antidepressant and nootropic effect. The use of AGM in the pediatric population is limited by the scarcity of data. In addition, few studies and case reports have been published on the use of AGM in patients with attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Considering this evidence, the purpose of this review is to report the potential role of AGM in neurological developmental disorders. AGM would increase the expression of the cytoskeleton-associated protein (ARC) in the prefrontal cortex, with optimization of learning, long-term memory consolidation, and improved survival of neurons. Another important feature of AGM is the ability to modulate glutamatergic neurotransmission in regions associated with mood and cognition. With its synergistic activity a melatoninergic agonist and an antagonist of 5-HT2C, AGM acts as an antidepressant, psychostimulant, and promoter of neuronal plasticity, regulating cognitive symptoms, resynchronizing circadian rhythms in patients with autism, ADHD, anxiety, and depression. Given its good tolerability and good compliance, it could potentially be administered to adolescents and children. |
format | Online Article Text |
id | pubmed-10216109 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102161092023-05-27 Agomelatine: A Potential Multitarget Compound for Neurodevelopmental Disorders Savino, Rosa Polito, Anna Nunzia Marsala, Gabriella Ventriglio, Antonio Di Salvatore, Melanie De Stefano, Maria Ida Valenzano, Anna Marinaccio, Luigi Bellomo, Antonello Cibelli, Giuseppe Monda, Marcellino Monda, Vincenzo Messina, Antonietta Polito, Rita Carotenuto, Marco Messina, Giovanni Brain Sci Review Agomelatine (AGM) is one of the latest atypical antidepressants, prescribed exclusively for the treatment of depression in adults. AGM belongs to the pharmaceutical class of melatonin agonist and selective serotonin antagonist (“MASS”), as it acts both as a selective agonist of melatonin receptors MT1 and MT2, and as a selective antagonist of 5-HT2C/5-HT2B receptors. AGM is involved in the resynchronization of interrupted circadian rhythms, with beneficial effects on sleep patterns, while antagonism on serotonin receptors increases the availability of norepinephrine and dopamine in the prefrontal cortex, with an antidepressant and nootropic effect. The use of AGM in the pediatric population is limited by the scarcity of data. In addition, few studies and case reports have been published on the use of AGM in patients with attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Considering this evidence, the purpose of this review is to report the potential role of AGM in neurological developmental disorders. AGM would increase the expression of the cytoskeleton-associated protein (ARC) in the prefrontal cortex, with optimization of learning, long-term memory consolidation, and improved survival of neurons. Another important feature of AGM is the ability to modulate glutamatergic neurotransmission in regions associated with mood and cognition. With its synergistic activity a melatoninergic agonist and an antagonist of 5-HT2C, AGM acts as an antidepressant, psychostimulant, and promoter of neuronal plasticity, regulating cognitive symptoms, resynchronizing circadian rhythms in patients with autism, ADHD, anxiety, and depression. Given its good tolerability and good compliance, it could potentially be administered to adolescents and children. MDPI 2023-04-27 /pmc/articles/PMC10216109/ /pubmed/37239206 http://dx.doi.org/10.3390/brainsci13050734 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Savino, Rosa Polito, Anna Nunzia Marsala, Gabriella Ventriglio, Antonio Di Salvatore, Melanie De Stefano, Maria Ida Valenzano, Anna Marinaccio, Luigi Bellomo, Antonello Cibelli, Giuseppe Monda, Marcellino Monda, Vincenzo Messina, Antonietta Polito, Rita Carotenuto, Marco Messina, Giovanni Agomelatine: A Potential Multitarget Compound for Neurodevelopmental Disorders |
title | Agomelatine: A Potential Multitarget Compound for Neurodevelopmental Disorders |
title_full | Agomelatine: A Potential Multitarget Compound for Neurodevelopmental Disorders |
title_fullStr | Agomelatine: A Potential Multitarget Compound for Neurodevelopmental Disorders |
title_full_unstemmed | Agomelatine: A Potential Multitarget Compound for Neurodevelopmental Disorders |
title_short | Agomelatine: A Potential Multitarget Compound for Neurodevelopmental Disorders |
title_sort | agomelatine: a potential multitarget compound for neurodevelopmental disorders |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216109/ https://www.ncbi.nlm.nih.gov/pubmed/37239206 http://dx.doi.org/10.3390/brainsci13050734 |
work_keys_str_mv | AT savinorosa agomelatineapotentialmultitargetcompoundforneurodevelopmentaldisorders AT politoannanunzia agomelatineapotentialmultitargetcompoundforneurodevelopmentaldisorders AT marsalagabriella agomelatineapotentialmultitargetcompoundforneurodevelopmentaldisorders AT ventriglioantonio agomelatineapotentialmultitargetcompoundforneurodevelopmentaldisorders AT disalvatoremelanie agomelatineapotentialmultitargetcompoundforneurodevelopmentaldisorders AT destefanomariaida agomelatineapotentialmultitargetcompoundforneurodevelopmentaldisorders AT valenzanoanna agomelatineapotentialmultitargetcompoundforneurodevelopmentaldisorders AT marinaccioluigi agomelatineapotentialmultitargetcompoundforneurodevelopmentaldisorders AT bellomoantonello agomelatineapotentialmultitargetcompoundforneurodevelopmentaldisorders AT cibelligiuseppe agomelatineapotentialmultitargetcompoundforneurodevelopmentaldisorders AT mondamarcellino agomelatineapotentialmultitargetcompoundforneurodevelopmentaldisorders AT mondavincenzo agomelatineapotentialmultitargetcompoundforneurodevelopmentaldisorders AT messinaantonietta agomelatineapotentialmultitargetcompoundforneurodevelopmentaldisorders AT politorita agomelatineapotentialmultitargetcompoundforneurodevelopmentaldisorders AT carotenutomarco agomelatineapotentialmultitargetcompoundforneurodevelopmentaldisorders AT messinagiovanni agomelatineapotentialmultitargetcompoundforneurodevelopmentaldisorders |